Trial
NCT00871689
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
—
Condition
Leukemia
Intervention
aldesleukin
Why stopped
Due to graft failure.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-28